SCHEMBL17069012

SCHEMBL17069012

Cc1c[nH]c(-c2cccc(C)c2C)n1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NUDT1 P36639 4/20 0.36
DCUN1D1 Q96GG9 2/20 0.36
SMN1; SMN2 Q16637 3/20 0.35
HPGD P15428 2/20 0.35
NPC1 O15118 2/20 0.35
ALDH1A1 P00352 2/20 0.35
RAB9A P51151 2/20 0.35
HTT P42858 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
MGAM O43451 4/20 0.34
GAA P10253 4/20 0.34
SI P14410 4/20 0.34
MGAM2 Q2M2H8 4/20 0.34
PIK3CD O00329 1/20 0.34
PIK3CA P42336 1/20 0.34
PIK3CB P42338 1/20 0.34
PIK3CG P48736 1/20 0.34
PRKDC P78527 1/20 0.34
AR P10275 3/20 0.33
TRPA1 O75762 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24360032 0.85 DCUN1D1 (0.50) DCUN1D1SMN1; SMN2HPGDNPC1ALDH1A1
SCHEMBL16481978 0.82 IDO1 (0.45) DCUN1D1SMN1; SMN2HPGDNPC1ALDH1A1
SCHEMBL31429629 0.82 MGAM (0.44) DCUN1D1SMN1; SMN2HPGDNPC1ALDH1A1
Hydrochloric Acid SCHEMBL4349754 0.81 REN (0.35) DCUN1D1SMN1; SMN2HPGDNPC1ALDH1A1
SCHEMBL17194918 0.80 TLR8 (0.37) DCUN1D1SMN1; SMN2HPGDNPC1ALDH1A1
SCHEMBL21163207 0.80 MEN1 (0.35) SMN1; SMN2HPGDNPC1ALDH1A1RAB9A
SCHEMBL17194967 0.80 NOTUM (0.35) SMN1; SMN2HPGDARTRPA1
Hydrochloric Acid SCHEMBL4345831 0.79 HPGD (0.38) DCUN1D1SMN1; SMN2HPGDNPC1ALDH1A1
SCHEMBL2555128 0.78 TRIM24 (0.37) NUDT1DCUN1D1SMN1; SMN2HPGDNPC1
SCHEMBL21091021 0.77 ADRA2A (0.31) SMN1; SMN2HPGDADRA2AADRA2BADRA2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2906553-B1 OREXIN RECEPTOR ANTAGONISTS WHICH ARE [ORTHO BI (HETERO )ARYL]-[2-(META BI (HETERO)ARYL)-PYRROLIDIN-1-YL]-METHANONE DERIVATIVES IDORSIA PHARMACEUTICALS LTD (CH) 2019-06-26 EP disclosed
US-9493446-B2 Orexin receptor antagonists which are [ortho bi-(hetero-)aryl]-[2-(meta bi-(hetero-)aryl)-pyrrolidin-1-yl]-methanone derivatives ACTELION PHARMACEUTICALS LTD. (CH) 2016-11-15 US disclosed
US-20150252032-A1 OREXIN RECEPTOR ANTAGONISTS WHICH ARE [ORTHO BI-(HETERO-)ARYL]-[2-(META BI-(HETERO-)ARYL)-PYRROLIDIN-1-YL]-METHANONE DERIVATIVES IDORSIA PHARMACEUTICALS LTD (CH) 2015-09-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150252032-A1 OREXIN RECEPTOR ANTAGONISTS WHICH ARE [ORTHO BI-(HETERO-)ARYL]-[2-(META BI-(HETERO-)ARYL)-PYRROLIDIN-1-YL]-METHANONE DERIVATIVES HCRTR2, HCRTR1, OXTR NUDT1 2772/4885DCUN1D1 3978/4885SMN1; SMN2 2096/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.